Page 1

Angiogenesis Modulators and therapeutics Market size Scope of the Study This report gives an insight into the types of Angiogenesis Modulators – Inhibitors and Stimulators -and their impact on various diseases. The study focuses on major angiogenesis inhibitors and their role in diseases such as cancer, dermatology, ophthalmology, rheumatology and other angiogenesis based diseases including endometriosis and inflammatory diseases. The emphasis is also given on major angiogenesis stimulators and their role in diseases such as cardiovascular disorders including ischemia, congestive heart failure, coronary artery disease, myocardial infarction and peripheral vascular disease and chronic wound care. The study provides global market analysis for angiogenesis therapeutic products by the above angiogenesis modulators and also by the disease areas such as cancer, cardiovascular disorders and other angiogenesis based diseases. The study includes estimates and projections for the total global angiogenesis therapeutic products market. Projections and estimates are also illustrated by geographic regions encompassing United States, Europe, Asia-Pacific and Rest of World. Business profiles of 34 major companies are discussed in the report. The report serves as a guide to global angiogenesis industry, as it covers more than 325 companies that are engaged in angiogenesis research, testing and supply of products and services. Major Contract Research Organizations and Universities serving angiogenesis industry are also covered in the Corporate Directory section of this report. Information related product developments, partnerships, collaborations, and mergers and acquisitions are also covered in the report. Angiogenesis Modulators report is an ideal research tool providing strategic business intelligence to the corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies, contract research organizations, biotechnology companies and drug approval authorities in- Gauging Competitive Intelligence  Identifying Key Growth Areas and Opportunities  Understanding Geographic Relevance to Product  Knowing Regional Market Sizes and Growth Opportunities and Restraints  Keeping Tab on Emerging Technologies  Equity Analysis  Tapping New Markets

Analytics and data presented in this report pertain to several parameters such as –  Global And Regional Market Sizes, Market Shares, Market Trends  Product (Global And Regional) Market Sizes, Market Shares, Market Trends  Technology Trends  Corporate Intelligence  Key Companies By Sales, Brands, Products  Consumer Behavioral Patterns

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 1


 Other Strategic Business Affecting Data

Research Methodology RI Technologies publishes business intelligence reports by going through a cycle of diligent research and analysis activity. Research is done using both online and offline resources. The study outline of this report is sketched on the following lines – global market analysis, regional market analysis, product segmentation, global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape, technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is also helpful for doing market evaluations, and estimating the market size for the future.

This report is uniquely researched and the methodology includes:  Need and Scope of Study  Product Definitions  Segmental Analysis  Regional Analysis  Exclusive Data Analytics  Corporate Intelligence  Feedback

Right from concept to final compilation of this report, both primary and secondary research methods are applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the information for authentication of our own findings. Secondary research includes government publications, investment research reports, web based surveys, website information of both companies and markets, and other offline resources such as print publications and CDs. Our compilation of easy to navigate PDF reports are essential value addition resources for leading and growing companies.

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 2


II. REPORT SYNOPSIS Angiogenesis The process of growth of new blood vessels from the available vascular bed is termed as angiogenesis. In general, this process takes place through development of embryo, during reproductive phase and wound repair. In case of aberrations such as tumorous growth, atherosclerosis and diabetic retinopathy, angiogenesis becomes inevitable due to variations in the positive and negative regulatory signals restraining the process. A proper balance of tumor neovascularization would open new doors for development of therapeutics for this disorder. The research patterns on anti-angiogenic drugs are focused on establishing the clinical veracity of these drugs. The success in this field has been elevated with the detection of improved role of hypoxia, growth factors, receptors, enzymes and bonding of cell molecules involved in the process. These innovations in the field have facilitated development of various medical aids such as receptor antagonists, and adhesion molecule blockers. Angiogenesis is responsible for tumor development. These cells are generated by angiogenic molecules in coordination with anti-angiogenic molecules. The growth of tumor is hindered or slowed down when the anti-angiogenic components are initiated in the body to balance the angiogenic molecules. This report analyzes global market for the following angiogenesis modulators and the therapeutic products for angiogenesis based diseases. Synopsis chapter of the report gives the summary of the global market for angiogenesis therapeutic products by angiogenesis modulators and by therapeutic areas for each geographic region – the US, Europe, Asia-Pacific and Rest of World.

Segmentation Exhibit 1. Segmentation of Global Angiogenesis Therapeutic Products Market by Angiogenesis Modulators and Therapeutic Areas Angiogenesis Modulators

Therapeutic Areas

Angiogenesis Inhibitors

Cancer

Angiogenesis Stimulators

Cardiovascular Ophthalmology *Other

*Includes Alzheimer’s, dermatology, rheumatology, chronic wounds, endometriosis and inflammatory diseases © RIT, 2013

Exhibit 2. Segmentation of Global Angiogenesis Cancer Therapeutic Products Market by Type Cancer Type Lung Cancer Colorectal Cancer Breast Cancer *Other *Includes Skin, Blood, Prostate, Renal Cell, Hepatocellular, Neuroendocrine, Esophageal, Gastrointestinal stromal tumor (GIST), Ovarian, Pancreatic and Stomach Cancers © RIT, 2013

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 3


Global Market Analysis Global market for Angiogenesis therapeutic products is projected to reach about US$ XX.XX billion by 2020 from an estimated US$ XX.XX billion in 2012, growing at a compounded annual growth rate (CAGR) of XX.XX% during the analysis period 2005-2020. Exhibit 3. Angiogenesis Therapeutic Products – Global Value Market Estimations & Predictions (20052020) in US$ Million Year

Value

2005

XX.XX

2006

XX.XX

2007

XX.XX

2008

XX.XX

2009

XX.XX

2010

XX.XX

2011

XX.XX

2012

XX.XX

2013

XX.XX

2014

XX.XX

2015

XX.XX

2016

XX.XX

2017

XX.XX

2018

XX.XX

2019

XX.XX

2020

XX.XX

CAGR%

XX.XX

© RIT Figures, 2013

US$ Million

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 4


Angiogenesis Modulators Analysis by Geographic Region Inhibitors The market in Europe is projected to reach about US$ XX.XX billion for angiogenesis inhibitors by 2020 from an estimated US$ XX.XX million in 2012, growing annually at a compounded rate of XX.XX % during the period 2005-2020. In 2015, the market is estimated to touch US$ XX.XX million. Germany was estimated the largest market in 2012 with market value of worth US$ XX.XX million, while United Kingdom follows Germany with US$ XX.XXmillion. Switzerland, excluding Rest of Europe, is projected to be the fastest growing market for angiogenesis inhibitors during 2005-2020 with a CAGR of XX.XX %. Exhibit 4. Angiogenesis Inhibitors – European Value Market Estimations & Predictions (2005-2020) in US$ Million for Germany, United Kingdom, France, Switzerland and Rest of Europe Year/Region

Germany

United Kingdom

France

Switzerland

Rest of Europe

Total

2005

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2006

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2007

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2008

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2009

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2010

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2011

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2012

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2013

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2014

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2015

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2016

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2017

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2018

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2019

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2020

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

CAGR%

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

© RIT Figures, 2013

US$ Million

2005

2006

2007

2008

Germany

2009

2010

2011

United Kingdom

2012

2013 France

2014

2015

2016

Switzerland

2017

2018

2019

2020

Rest of Europe

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 5


III. MARKET DYNAMICS MARKET OVERVIEW Global Market Analysis Global market for angiogenesis therapeutic products is projected to reach about US$ XX.XX billion by 2020 from an estimated US$ XX.XX billion in 2012, growing at a Compounded Annual Growth Rate (CAGR) of XX.XX % during the analysis period, 2005-2020. Global Angiogenesis market for 2015 is estimated at US$ XX.XX billion. The United States is the largest market for angiogenesis therapeutic products in 2012 with a share of XX.XX %, valued at an estimated US$ XX.XX billion, and is projected to reach US$ XX.XX billion by 2020 to retain its position with a share of XX.XX %. The US is also projected to be the second fastest growing market with a CAGR of XX.XX %, excluding Rest of World, during the analysis period. Europe is the second largest (XX.XX % market share in 2010) market during the same analysis period, while Asia-Pacific is projected to be the fastest growing (XX.XX % during 2005-2020) market. In 2012, the market for angiogenesis therapeutic products in Europe and Asia-Pacific is estimated at US$ XX.XX billion and US$ XX.XX billion respectively. Rest of World (consisting of Latin America, Africa and Middle East) region’s market for angiogenesis products is estimated at US$ XX.XX billion in 2012.

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 6


Exhibit 5. Angiogenesis Therapeutic Products – Global Value Market Estimations & Predictions (20052020) in US$ Million for United States, Europe, Asia-Pacific and Rest of World Year /Region

United States

Europe

Asia-Pacific

Rest of World

Total

2005

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2006

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2007

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2008

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2009

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2010

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2011

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2012

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2013

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2014

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2015

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2016

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2017

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2018

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2019

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

2020

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

CAGR%

XX.XX

XX.XX

XX.XX

XX.XX

XX.XX

© RIT Figures, 2013

US$ Million

2005

2006

2007

2008

United States

2009

2010

2011

Europe

2012

2013

2014

2015

Asia-Pacific

2016

2017

2018

2019

2020

Rest of World

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 7


IV. PRODUCT/TECHNOLOGY RESEARCH

Angiogenesis – The Growth of New Blood Vessels The process of growth of new blood tissues from the available vascular bed is termed as Angiogenesis. In general this process takes place through development of embryo, during reproductive phase and wound repair. In case of aberrations like tumorous growth, atherosclerosis and diabetic retinopathy, angiogenesis becomes inevitable due to variations in the positive and negative regulatory signals restraining the process. A proper balance of tumor neovascularization would open new doors in development of therapeutics for this disorder. The research patterns on anti-angiogenic drugs are focused to establish the clinical veracity of these drugs. The success in this field has been elevated with the detection of improved role of hypoxia, growth factors, receptors, enzymes and bonding of cell molecules involved in the process. These innovations in the field have facilitated development of various medical aids such as receptor antagonists, and adhesion molecule blockers. Angiogenesis is the main system responsible for tumor development. These cells are generated by angiogenic molecules in coordination with anti-angiogenic molecules. The growth of tumor is hindered or slowed down when the anti-angiogenic components are initiated in the body to balance the angiogenic molecules. The maximum limit of a tumor growth is 2 millimeters and is extendable along with vascularization. The role played by angiogenesis in the development of tumor is very critical. It is responsible for supply of oxygen, other nutrients to the cells and disposal of metabolic wastes effectively. Hence the tumor growth is considered incomplete without the intervention of angiogenesis. Tumors obtain angiogenic phenotype during a regular succession of the growth. This is considered as important biomarker for the treatment of cancer. The tumor cells produce some significant angiogenic and anti-angiogenic molecules such as VEGF, bFGF, angiostatin, and endostatin respectively. There is significant evidence to support this. Both these categories of molecules have their own way of stimulating tumor angiogenesis. The balance between both these molecules is the determinant of tumor growth. In most of the cases, as time elapses, mutational inactivation in anti-angiogenic genes become responsible for balance of angiogenic molecules that ultimately is responsible for tumor growth. Harmonizing of anti-angiogenic molecules over angiogenic molecules would direct to the reticence of tumor growth and even deterioration. The latest advancements in this field have enabled the development of numerous anti-angiogenic components like angiostatin, endostatin and a few synthetic anti-angiogenic components. The large-scale production of these components by employing recombinant DNA technique is being explored. Antiangiogenic molecules are responsible for regulation of apoptosis, minimizing of endothelial cell propagation and some of the collective actions. The research with angiostatin and endostatin by employing model animals has provided challenging results in the healing process of tumors and metastasis. Anti-angiogenic factors play a vital role in the formation of new blood tissues from the normal cells. The chemotherapeutic medicines attack the tumor cells. The repeated use of these therapies would reduce the immunity of the body and breed various tissue related disorders. The research studies have highlighted the negative effects of anti-angiogenic factors and their role in production of synergetic effects.

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 Š RI Technologies - www.researchimpact.com Sample Page - 8


Exhibit 6. Angiogenesis Inhibitors (2005-2020): Global Analysis (Current & Future) of Patients Treated in Million Year

Patients

2005

XX.XX

2006

XX.XX

2007

XX.XX

2008

XX.XX

2009

XX.XX

2010

XX.XX

2011

XX.XX

2012

XX.XX

2013

XX.XX

2014

XX.XX

2015

XX.XX

2016

XX.XX

2017

XX.XX

2018

XX.XX

2019

XX.XX

2020

XX.XX

CAGR%

XX.XX

© RIT Figures, 2013

Million

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

About RI Technologies RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 9


monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging technologies in areas of discovery, design and development.

Research – As Good as the Methodology is! 

Gauging Competitive Intelligence

Identifying Key Growth Areas and Opportunities

Understanding Geographic Relevance to Product

Knowing Regional Market Sizes and Growth Opportunities and Restraints

Keeping Tab on Emerging Technologies

Equity Analysis

Tapping New Markets

© COPYRIGHT The copyright and publication rights to all RI Technologies' reports and other products are the property of the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of the material without express permission is not allowed. The buyer, under no circumstances, shall license, resell or repackage, or sell data without prior permission of the company.

DISCLAIMER RI Technologies sells content in good faith. The company is not liable to the buyer for any implications arising out of the usage of data for any particular purpose. The company makes no representations or warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for data compilation and presentation, the company does not accept any responsibility for findings in the study which are a cumulative effort of primary and secondary research resources. The studies do not endorse or promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage of the data.

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 10


RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013 Š RI Technologies - www.researchimpact.com Sample Page - 11

Angiogenesis modulators and therapeutics Market report  

This report gives an insight into the types of Angiogenesis Modulators – Inhibitors and Stimulators -and their impact on various diseases. T...

Read more
Read more
Similar to
Popular now
Just for you